EnglishFrançais
Log in
(0)

European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- Free -

The European Pharmacopoeia (Ph. Eur.) Monograph 0478 is the foundational quality standard for tablets intended for oral administration in Europe. Published by the European Directorate for the Quality of Medicines & HealthCare (EDQM), it establishes legally binding requirements for the definition, production, and testing of diverse tablet forms to ensure patient safety and therapeutic efficacy. 1. Scope and Definition

According to the monograph, tablets are solid preparations, each containing a single dose of one or more active substances. They are primarily obtained by compressing uniform volumes of particles but can also be manufactured via extrusion, moulding, or freeze-drying (lyophilisation).

The monograph explicitly excludes preparations like lozenges, oral pastes, and oral gums , which are covered under separate general chapters such as Oromucosal Preparations (1807). 2. Recognized Categories of Tablets

Monograph 0478 distinguishes several specific categories, each with tailored requirements:

Uncoated Tablets: Single or multi-layer tablets without specific release-modifying excipients.

Coated Tablets: Finished with layers of resins, sugars, or polymers (film-coated) to protect the core or mask taste. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Modified-Release: Includes prolonged-release and pulsatile-release tablets designed to alter the rate or timing of drug delivery.

Gastro-Resistant: Delayed-release tablets intended to resist gastric fluid and release the active substance in the intestinal tract.

Effervescent: Formulated with carbonates to react in water and release carbon dioxide for rapid dispersion.

Orodispersible and Soluble: Tablets designed to disperse rapidly in the mouth or dissolve in water before administration. 3. Production and Quality Control Requirements

Manufacturers must implement measures to ensure tablets possess sufficient mechanical strength to withstand handling. Standardized testing includes: The European Pharmacopoeia (Ph

Resistance to Crushing: Measured in Newtons, typically on a sample of 10 tablets to determine the force required for disruption.

Friability: Assessed via general chapter 2.9.7 to ensure tablets do not crumble or break during processing or transport.

Subdivision (Scoring): For tablets with break-marks, the efficacy of the mark is assessed by weighing subdivided parts. Not more than one out of 30 parts may fall outside 85% to 115% of the average mass. 4. Mandatory Pharmacopoeial Tests

Compliance with Monograph 0478 requires several critical laboratory tests, often cross-referencing general chapters:

Disintegration (2.9.1): Uncoated tablets must typically disintegrate within 15 minutes in water at 37°C. Coated tablets (non-film) are allowed up to 60 minutes. In the absence of a specific monograph for

Dissolution (2.9.3): Since January 2018, revised standards mandate a suitable dissolution test for immediate-release forms unless otherwise justified.

Uniformity of Dosage Units (2.9.40): Ensures each tablet in a batch contains the correct amount of active pharmaceutical ingredient (API). Summary of Standard Disintegration Times Tablet Type Max Time Allowed 15 minutes Film-coated 30 minutes Other Coated 60 minutes Soluble/Dispersible Water (15–25°C) Effervescent Water (15–25°C) Revised Ph. Eur. Chapter Tablets - gmp-compliance.org

European Pharmacopoeia (Ph. Eur.) — Monograph: Tablets (0478)

Related Substances (Degradation Products)

A specific requirement of 0478: "For tablets, the test for dissolution is a more stringent measure of bioavailability than disintegration, but it does NOT replace the need for impurity profiling."

The Spectrum of Uniformity

One of the most critical sections of 0478 deals with Uniformity of Dosage Units. In a manufacturing run of millions of pills, how do you ensure every single one has the exact same amount of medicine?

The monograph references strict testing methods to ensure that the variance between tablets is statistically insignificant. This is where the "mass variation" test meets the "content uniformity" test. If a tablet contains a tiny amount of potent API (like a hormone or an opioid), weighing the tablet isn't enough; chemists must assay the content of individual units. 0478 dictates when to use which method, ensuring that a patient never receives a "super-potent" or "sub-potent" dose.

Why 0478 matters — impact in practice

For Prolonged-release (Sustained-release) Tablets

2. Scope and Definitions

The "General" Specifics

Monograph 0478 is a general monograph. This is a crucial distinction. It does not describe a specific drug (like paracetamol or ibuprofen); rather, it sets the universal rules for all tablets. Whether it is a simple painkiller, a complex modified-release heart medication, or an effervescent vitamin C tablet, 0478 applies.

It defines the tablet fundamentally: "Solid preparations each containing a single dose of one or more active substances." But the brilliance of the monograph lies in how it navigates the variety of this format.

9. Checklist for Compliance (Summary)